Sign In
Buy CRBU
$2.00
-0.320 (-13.79%)
At Close: Jun 03, 2026
NEW YORK , Dec. 27, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) and certain of
NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed
NEW YORK CITY, NY / ACCESSWIRE / December 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU) and cert
Rosen Law Firm Urges Caribou Biosciences, Inc. (NASDAQ: CRBU) Investors to Contact the Firm for Information About Their Rights
06:23pm, Thursday, 26'th Dec 2024
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Caribou Biosciences, Inc. (NASDAQ: CRBU) secu
NEW YORK CITY, NY / ACCESSWIRE / December 26, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou
Pomerantz Law Firm Announces the Filing of a Class Action Against Caribou Biosciences, Inc. and Certain Officers - CRBU
07:15pm, Tuesday, 24'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 24, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU) and cert
Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:57am, Monday, 16'th Dec 2024
Caribou Biosciences (CRBU) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 20'th Nov 2024
BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. announces that the United States District Court for the Northern District of California has approved the following announcemen
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
07:06pm, Wednesday, 06'th Nov 2024
Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.12 per share a year ago.
Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing
03:53am, Monday, 30'th Sep 2024
Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform
Caribou Biosciences to Participate in Upcoming Investor Conferences
04:00pm, Monday, 26'th Aug 2024
BERKELEY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced company leadersh
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
01:00pm, Monday, 19'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ:CRBU). Such investors are a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
10:50pm, Saturday, 17'th Aug 2024
NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU). Such investors are ad
